vs
Side-by-side financial comparison of Village Farms International, Inc. (VFF) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.2M, roughly 1.1× Village Farms International, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 19.9%, a 55.8% gap on every dollar of revenue.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
VFF vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.2M | $13.7M |
| Net Profit | $2.4M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | — | -86.5% |
| Net Margin | 19.9% | 75.7% |
| Revenue YoY | 31.5% | — |
| Net Profit YoY | 128.2% | 179.1% |
| EPS (diluted) | $0.01 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.2M | $13.7M | ||
| Q3 25 | $66.7M | $19.1M | ||
| Q2 25 | $59.9M | $8.1M | ||
| Q1 25 | $77.1M | $2.9M | ||
| Q3 24 | $54.9M | — | ||
| Q2 24 | $53.6M | — | ||
| Q1 24 | $78.1M | — | ||
| Q4 23 | $-48.3M | — |
| Q4 25 | $2.4M | $10.4M | ||
| Q3 25 | $10.2M | $-16.3M | ||
| Q2 25 | $26.5M | $-15.8M | ||
| Q1 25 | $-6.7M | $-13.3M | ||
| Q3 24 | $-820.0K | — | ||
| Q2 24 | $-23.5M | — | ||
| Q1 24 | $-2.9M | — | ||
| Q4 23 | $-25.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | 47.9% | — | ||
| Q2 25 | 37.3% | — | ||
| Q1 25 | 14.7% | — | ||
| Q3 24 | 24.8% | — | ||
| Q2 24 | 25.4% | — | ||
| Q1 24 | 19.9% | — | ||
| Q4 23 | — | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | 23.3% | -10.1% | ||
| Q2 25 | 20.8% | -177.7% | ||
| Q1 25 | -8.0% | -472.7% | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | -43.5% | — | ||
| Q1 24 | -3.0% | — | ||
| Q4 23 | — | — |
| Q4 25 | 19.9% | 75.7% | ||
| Q3 25 | 15.3% | -85.4% | ||
| Q2 25 | 44.2% | -196.0% | ||
| Q1 25 | -8.7% | -452.7% | ||
| Q3 24 | -1.5% | — | ||
| Q2 24 | -43.9% | — | ||
| Q1 24 | -3.7% | — | ||
| Q4 23 | 52.8% | — |
| Q4 25 | $0.01 | $-3.74 | ||
| Q3 25 | $0.08 | $-0.11 | ||
| Q2 25 | $0.24 | $-0.16 | ||
| Q1 25 | $-0.06 | $-0.18 | ||
| Q3 24 | $-0.01 | — | ||
| Q2 24 | $-0.21 | — | ||
| Q1 24 | $-0.03 | — | ||
| Q4 23 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $81.2M | $137.5M |
| Total DebtLower is stronger | $33.7M | — |
| Stockholders' EquityBook value | $299.9M | $35.3M |
| Total Assets | $423.1M | $154.7M |
| Debt / EquityLower = less leverage | 0.11× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.2M | $137.5M | ||
| Q3 25 | $82.6M | $103.8M | ||
| Q2 25 | $60.0M | $121.6M | ||
| Q1 25 | $15.1M | $89.1M | ||
| Q3 24 | $28.7M | — | ||
| Q2 24 | $29.7M | — | ||
| Q1 24 | $26.7M | — | ||
| Q4 23 | $30.3M | — |
| Q4 25 | $33.7M | — | ||
| Q3 25 | $34.6M | — | ||
| Q2 25 | $39.1M | — | ||
| Q1 25 | $39.2M | — | ||
| Q3 24 | $43.3M | — | ||
| Q2 24 | $44.4M | — | ||
| Q1 24 | $46.1M | — | ||
| Q4 23 | $48.1M | — |
| Q4 25 | $299.9M | $35.3M | ||
| Q3 25 | $295.4M | $-8.1M | ||
| Q2 25 | $284.3M | $7.1M | ||
| Q1 25 | $248.3M | $10.7M | ||
| Q3 24 | $274.4M | — | ||
| Q2 24 | $275.2M | — | ||
| Q1 24 | $296.2M | — | ||
| Q4 23 | $299.6M | — |
| Q4 25 | $423.1M | $154.7M | ||
| Q3 25 | $418.4M | $133.7M | ||
| Q2 25 | $403.7M | $133.8M | ||
| Q1 25 | $377.1M | $103.7M | ||
| Q3 24 | $417.8M | — | ||
| Q2 24 | $425.4M | — | ||
| Q1 24 | $458.4M | — | ||
| Q4 23 | $464.0M | — |
| Q4 25 | 0.11× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.16× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — | ||
| Q4 23 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | 90.8% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $24.4M | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | $-6.4M | $29.0M | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $5.7M | — | ||
| Q1 24 | $-50.0K | — | ||
| Q4 23 | $-1.5M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $22.6M | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | $-8.9M | $29.0M | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $4.8M | — | ||
| Q1 24 | $-1.9M | — | ||
| Q4 23 | $-2.2M | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | 33.9% | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | -11.6% | 988.3% | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 9.0% | — | ||
| Q1 24 | -2.5% | — | ||
| Q4 23 | 4.6% | — |
| Q4 25 | 90.8% | 0.7% | ||
| Q3 25 | 2.7% | 0.0% | ||
| Q2 25 | 4.6% | 5.0% | ||
| Q1 25 | 3.3% | 0.8% | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 2.4% | — | ||
| Q4 23 | -1.6% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | 2.39× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
XLO
Segment breakdown not available.
